Aarti Pharmalabs Reports Strong Q2 FY27 Operating Performance and Expansion Plans
Aarti Pharmalabs Ltd · Investor Presentation · 29 Oct 2026, 7:00 pm
Aarti Pharmalabs Reports Strong Q2 FY27 Operating Performance and Expansion Plans Aarti Pharmalabs delivered strong Q2 FY27 consolidated operational revenue of INR 6,105 Mn (up 45.9% YoY, 13.9% QoQ), with EBITDA surging 80.2% YoY to INR 1,346 Mn and PAT rising 248.8% YoY to INR 715 Mn. Xanthine Derivatives contributed 50% of revenue, followed by API/Intermediates at 30% and CDMO/CMO at 13%. The firm is investing INR 149 Cr in Atali Block 2 (~405 KL) for CDMO, targeting commercialization by H2 FY28, while guiding for a 15–18% revenue and EBITDA CAGR over 3–4 years.
Original exchange filing (PDF)
More announcements from Aarti Pharmalabs Ltd
- Intimation of sad demise of Promoter and Chairman Emeritus of the Company · 16 Nov 2026
- Q2 FY 27 Earnings Call Transcript · 04 Nov 2026
- Audio Recording of Conference Call for Investor and Analysts · 30 Oct 2026
- Please find enclosed · 29 Oct 2026
- Please find enclosed · 29 Oct 2026
- Please find enclosed · 29 Oct 2026
- Aarti Pharmalabs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 29 Oct 2026
- Please find enclosed · 29 Oct 2026
